Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus Crispatus M247 in HPV Low-grade Cervical Lesions
NCT05808816Phase 4Unknown
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2021
- Primary completion
- Feb 2023
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lactobacillus crispatus M247 in human papillomavirus infection, cervical intraepithelial neoplasia (CIN) and bacterial vaginosis (BV), sponsored by Policlinico Gemelli. Primary endpoint: Vaginal microbiota genetic profile changes at 5 months. Status: unknown.
02
Drugs
lactobacillus crispatus M247
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT05808816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05808816.